Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly
This retrospective observational study suggests that adults initiating compounded injectable tirzepatide at microdoses of 1–2 mg/week experience progressive weight loss over time, with mean reductions ranging from 2.18% to 6.10% across 14- to 89-day observation windows, though the findings remain hypothesis-generating due to the uncontrolled design and sparse long-term follow-up.